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Abstract: The recent years have seen the emergence of diseases which have spread very quickly all around the world either through human travels like SARS or animal 
migration like avian flu. Among the biggest challenges raised by infectious emerging diseases, one is related to the constant mutation of the viruses which turns them into 
continuously moving targets for drug and vaccine discovery. Another challenge is related to the early detection and surveillance of the diseases as new cases can appear just 
anywhere due to the globalization of exchanges and the circulation of people and animals around the earth, as recently demonstrated by the avian flu epidemics. For 3 years 
now, a collaboration of teams in Europe and Asia has been exploring some innovative in silico approaches to better tackle avian flu taking advantage of the very large 
computing resources available on international grid infrastructures. Grids were used to study the impact of mutations on the effectiveness of existing drugs against H5N1 and 
to find potentially new leads active on mutated strains. Grids allow also the integration of distributed data in a completely secured way. The paper presents how we are 
currently exploring how to integrate the existing data sources towards a global surveillance network for molecular epidemiology. 
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INTRODUCTION 
Emerging diseases know no frontier. Public health authorities 
have identified the risk they represent and developed national 
and international policies to address them. The challenge to 
achieve early response is to collect critical data and to quickly 
process them in order to launch a prompt alert. However, the 
relevant data are often coming from multiple sources which are 
widely distributed geographically. Indeed, experience with 
SARS and Avian Flu has clearly shown that the emerging 
diseases have to be monitored at a world level. The emergence 
of these diseases has also triggered the development of 
epidemiological surveillance networks. These networks are 
collecting data but do not provide the facilities to process them. 
International agencies like FAO or WHO make a significant 
corpus of data publicly available on central servers. These 
servers provide very useful information to the decision makers 
and to the public opinion but can not be considered for raising an 
alert in case of pandemics. More relevant are the specialized 
molecular biology databases which have been set up for 
influenza viruses but they do not provide the latest strains 
sequenced. 
 
Grid technology has been quickly evolving in the last 10 years. 
Today, it has reached a level of maturity in the field of 
distributed computing and data management, which makes it a 
natural choice to implement a surveillance network for emerging 
diseases. It allows federating distributed data sources, querying 
them remotely and on demand mobilizing large CPU resources 
to analyse them. In this paper, we discuss opportunities provided 
by the grid technology to improve the global response to 
emerging diseases by improving the collection, availability and 
accessibility of disease related data for molecular epidemiology 
and in silico drug discovery as well as developing an alert 
system. The method is to develop an international network of 
data repositories integrated into a data grid. Through the access 
and query of these data, services are offered to the research 
community, allowing the network to work as an alert system for 
public health authorities. The grid added value compared to the 
other existing efforts is that no movement of data is needed as 
they are queried where they are produced. Moreover, services 
are provided on demand for data analysis on the grid computing 
resources.  
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Such a network is well fitted to address the two main concerns of 
the international community which are the evolution of the virus 
and its capacity for human-to-human transmission, through the 
set-up of two families of services: 
- Molecular epidemiology: once a new virus stream has been 
sequenced, its comparison to the previously identified streams 
allows measuring the virus evolution.  
- Virtual screening: in silico docking allows monitoring the 
impact of mutations on the existing drugs and rapid 
identification of new hits on mutated strains.  
Today, thank to the progresses in web and grid technologies, 
building such a surveillance network is more a political than a 
technical challenge. In this paper, we will provide examples of 
services currently operated on grid infrastructures, which fit 
exactly the requirements of the proposed network.  
 
The paper is organized as follows: 
- In section 1, we discuss the context of avian flu epidemics on 
one side and grid technology on the other side. 
- In section 2, we present how grids are already used to do 
virtual screening on neuraminidase N1 and to study the impact 
of mutations on the efficiency of the existing drugs targeting this 
enzyme. 
- In section 3, we provide an example of a grid enabled disease 
specific surveillance network in the Auvergne region in France 
federating databases with patient anatomical data and in a later 
stage integrating oncogenetics data 
- In section 4, we present the vision for a surveillance network 
on avian flu 
- And section 5 presents some conclusions and perspectives. 
CONTEXT 
Medical context: emerging diseases, a growing threat to 
public health 
Avian influenza virus, which has claimed its first human victim 
in 1997 in Hong Kong, became the primary health concern of the 
21st century. Although various strains of avian influenza have 
been recognized for decades, the « highly pathogenic avian 
influenza virus of type A of subtype H5N1 » is a likely source of 
the next human influenza pandemic [1]. In its latest report from 
September 2008, WHO reports 387 human cases in 15 countries 
and 245 deaths between 2003 and 2008, mostly in Asia [2]. 
H5N1 is primarily a pathogen of poultry; more than 200 million 
poultry died because of this virus. Human acquired the virus by 
having direct or close contact with H5N1-infected poultry or 
poultry products [3]. More than 60 % of human infections have 
been fatal, so far the spread of avian influenza viruses from one 
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ill person to another has been reported very rarely. But the 
biggest fear remains the risk of the reassortment of an avian 
influenza virus with a human (or other non-avian) influenza 
virus, more dangerous and difficult to combat [4]. The ability of 
the international community to respond efficiently to the 
possible emergence of a human-to-human transmissible avian 
influenza virus depends on its capacity to quickly assess any 
evolution of the disease. Since 1997, the virus has spread 
through Asia, the Middle East, Europe and Africa. This global 
and rapid spread of H5N1 induces the necessity to improve 
pandemic preparedness and communication, early detection and 
surveillance, containment and responses systems. Use of drugs 
against influenza virus could represent a first line defence 
against a new pandemic, allowing the control of the infection 
until sufficient quantities of a suitable vaccine can be produced. 
Zanamivir (Relenza®) and oseltamivir (Tamiflu®) are available 
antiviral molecules inhibiting a key viral protein: neuraminidase 
(NA). Unfortunately, the report of development of drug 
resistance causes growing concern [5].  
 
Grid technology, presented in next section, is a relevant choice 
to address evolution and transmission of avian influenza by 
setting up a surveillance network for federating distributed data, 
querying them remotely and performing analyses on demand.  
Technical context: grids, an emerging technology for 
mutualising and federating data and computing resources 
Grid computing is an exciting new technology promising to 
revolutionise many services already offered by the internet. 
Grids are defined as a fully distributed, dynamically 
reconfigurable, scalable and autonomous infrastructure to 
provide location independent, pervasive, reliable, secure and 
efficient access to a coordinated set of services encapsulating 
and virtualizing resource [6]. This new paradigm offers rapid 
computation, large-scale data storage and flexible collaboration 
by harnessing together the power of a large number of 
commodity computers or clusters of other basic machines. The 
grid was devised for use in scientific fields, such as particle 
physics and bioinformatics, in which large volumes of data, or 
very rapid processing, or both, are necessary. Unsurprisingly, the 
grid has also been used in a number of ambitious medical and 
healthcare applications such as MammoGrid [7] or Health-e-
Child [8]. A ‘healthgrid’ is an innovative use of this emerging 
information technology to support broad access to rapid, cost-
effective and high quality healthcare [9]. 
 
Well-identified areas of relevance of the grid paradigm are 
epidemiology and drug discovery. Epidemiology focused on 
population-level research requires access to distributed, critically 
sensitive and heterogeneous data, resulting in overall costly 
computing processes. Users ought to be able to take for granted 
that the security mechanisms are sufficient to protect their data, 
that the results of their research will be private and available to 
third parties only if desirable, that the system will meet the 
concerns of the ethical and legal committees of their research 
institutions, that the services are reliable, efficient and 
permanent, that they do not have to change significantly their 
current procedures, protocols or workflow and finally that the 
data is somehow automatically organised and gathered, thus 
available for further exploitation. Early attempts at 
epidemiological applications of grids [10] have demonstrated 
their relevance for patient customized research. 
The discovery and development of new drugs is very costly and 
attrition rates are high. Initiatives to reduce the rate of attrition 
during later phases of development are clearly desirable and if 
successfully implemented will reduce costs. Predictive 
pharmacology at the discovery research stage has been identified 
as one of the key bottlenecks in the pharmaceutical R&D process 
[11]. As well, knowledge management is essential to leveraging 
the potential of genomics and proteomics and to analyse the 
huge amount of information in an integrated way. In this context, 
the computing power of the grids is starting to be exploited for 
the identification of new promising compounds through virtual 
screening [12].  
In the next section, we are going to present briefly some 
significant results obtained in the field of drug discovery on 
avian flu thank to grid infrastructures.  
CURRENT USES OF GRID TECHNOLOGY FOR DRUG 
DISCOVERY ON AVIAN FLU 
In silico virtual screening 
In 2005, the WISDOM (Wide In Silico Docking On Malaria) 
addressed successfully in silico high-throughput screening on 
grid infrastructures to look for new inhibitors against enzymes 
implicated in malaria, reducing the time and the cost of 
pharmaceutical development for this neglected disease [13]. 
Based on this first successful experience, in 2006, it was decided 
to perform a computational challenge to deploy large virtual 
screening of 300,000 chemical compounds selected from ZINC 
database (http://zinc.docking.org/) and a chemical combinatorial 
library against 8 variants of neuraminidases predicted by 
homology modelling. NA structures were predicted because no 
NA subtype 1 (NA1) was available for structural study. 
Afterwards, crystal structures published for NA1 [14] were in 
good agreement with our modelled structures with a RMSD of 
1.4 Å (all atoms). In order to model complexes of candidate 
compounds to structures of NA binding sites, the Autodock 
program [15] was deployed. This program allows fast 
calculation of binding energies of possible binding poses. 
Compounds are ranked based on docking score and binding 
mode. Grid technology enables to provide the computational and 
storage resources required for the in silico experiment. During 
six weeks, 2000 CPUs on the EGEE (Enabling Grid for E-
sciencE) grid infrastructure have been mobilized [16] to perform 
4 million docking calculations, which would require 100 years 
on one single computer. Two grid environments were used in 
this data challenge in order to have efficient and interactive 
control of massive molecular dockings: WISDOM and DIANE 
[17]. About 600 gigabytes of output data were produced and 
needed to be post-processed to avoid false positives. Few 
hundred chemical compounds were finally selected and tested in 
a biochemical laboratory in order to evaluate in vitro inhibition 
activity. 
A wild type NA from H5N1 influenza virus strain 
A/Vietnam/1203/04 was prepared using E. coli expression 
systems and purified to single protein on a SDS-PAGE. NA 
activity was determined using MUNANA [2’-(4-
methylumberlliferyl)-alpha-D-N-acetyl neuraminic acid] as a 
fluorogenic substrate [18]. Inhibition activity of NA was 
determined by incubating enzyme solution with 40 mM sodium 
phosphate buffer (pH 7.2), MUNANA, and with or without 
ligands. Fluorescence was read with a fluorescence plate reader 
SoftMax Pro 5 (Molecular Devices, USA) using excitation and 
emission wavelengths of 362 nm and 448 nm. Among 185 
compounds tested 79 (42.9%) compounds showed inhibition for 
NA activity of H5N1, and 59 compounds (31.9%) showed same 
or better activity than that of oseltamivir which is a general 
inhibitor for NA of H5N1. In near future, mutant forms of NA 
will be tested in laboratory to allow correlation with results 
obtained in silico explained in next paragraph.  
Successfully validated in vitro, this virtual screening process can 
be routinely performed when a new NA mutation appears 
allowing a fast in silico answer which can be really useful to 
evaluate the impact of enzyme changes. Moreover, other key 
viral proteins can be investigated. Thanks to the grid large 
storage capacity and smart data management services, virtual 
data produced can be massively stored and easily accessed. 
Study of the impact of mutations on the efficiency of existing 
drugs  
NA1 structures, including one with original sequence (noted as 
original type) and five with different single point mutation, 
namely T01 (E119A), T02 (E119D), T03 (H274F), T04 
(H274Y), and T05 (R293K), in their binding sites, were 
established. Additionally, based on molecular dynamics 
simulation, a unique amino acid, Y344, in NA1 can pose either 
open or close conformation to binding pocket. The open 
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conformer is included in original type, noted T13, and E119A 
mutant, noted T07, for measuring its effects. 
A library of 308,585 compounds, including five known active 
compounds (Scheme. (1)), was docked into the binding site of 
NA1 using Autodock3.0.5 [15]. The docking energy of each 
pose was computed by Autodock and was used as an indication 
of inhibiting potential. The known active compounds were 
applied as the threshold of screening hits. 
As shown in Fig. (1), after ranking docked poses by their 
computed docking energies, the compound library distributed 
normally among -18kcal/mol to -2 kcal/mol. Two known potent 
drugs (GNA:zanamivir; G39: oseltamivir) presented within the 
top 5% of all compounds against target T06 (original type); two 
less potent inhibitors (DAN and 4AM) fell behind top 15%, 
which difference should be enough to discriminate between hits 
and non-hits. Furthermore, by referring to both positive controls, 
large portion of less active compounds (5% cutoff) were 
successfully filtered. In overall, our modelling effectively 
extracts potential hits and results in a suggested focus library for 
experimental assay. 
Changes of compound docking energies occurred in most 
mutants (Fig. (2)), the variants T01(E119A), T03(H274F), and 
T05(R293K) have greater impacts on the hits, whose docking 
energy better than -14.0 kcal/mol against T06. This observation 
agreed with other studies reported in the literature [19, 20]. It 
was also interesting to notice that the “open” and “close” 
conformation of Tyr344 (in T07 and T13) has obvious effects on 
the compound binding. Therefore, incorporation of interacting 
with Y344 should be considered in the future drug design. 
Knowing this effect has resulted in synthesis of highly potent 
inhibitor [21]. 
Mutation effects of known inhibitors may be predicted with 
similar method, as illustrated in Fig. (3), the docking energy of 
GNA (zanamivir) dropped from -14.7 kcal/mol to -12.7kcal/mol 
owing to the mutation of Glu119 to Ala (target T01). In general, 
G39 (oseltamivir) was more sensitive to the mutation than GNA 
at the sites of  E119 and H274 (Table. (1)). 
 
The next section introduces the use of distributed data for cancer 
surveillance network and the benefits of a grid environment in 
this case for secured access on data. 
GRIDS FOR EPIDEMIOLOGY: EXAMPLE OF A 
CANCER SURVEILLANCE NETWORK  
We would like to illustrate the interest of the grid approach for 
accessing distributed biological or medical data by taking the 
example of a surveillance network currently under design in the 
Auvergne region in the field of oncology. This network aims at 
improving the exchange of information between the public and 
private actors involved in the surveillance of cancers including 
the anatomical pathology, cytopathology laboratories, the 
associations in charge of the early detection programs, the local 
and national epidemiological services and possibly the patients. 
In France, the national program for early diagnosis of breast 
cancer is operated by associations, which are in charge of 
inviting through advertisement all women above 50 years old to 
undergo breast examination by mammography every three years. 
If some women are positively detected with tumours, the 
associations are in charge of providing a second diagnosis on the 
mammograms and following up on the medical process the 
patients are undergoing. This involves collecting the anatomical 
pathology data about the tumour which are stored by the 
laboratories in charge of biopsies. Presently, the patient data 
stored in laboratories are faxed on request or carried out by hand 
to the associations where they are registered again on a local 
computer. This process is costly and errors prone as data have to 
be typed and reinterpreted twice. Another alternative is for the 
associations to query the databases of the anatomical pathology 
laboratories on demand. The grid technology is particularly well 
fitted for such an approach: indeed, a grid federating the 
databases (see Fig. (4)) would provide a secured framework 
where the patient data are left in the laboratories and where some 
identified users from the associations deploy distributed queries 
on the data to fill their local patient file. Other customers of the 
data in the anatomical pathology laboratories are the 
epidemiological services of the National Institute for Sanitary 
Watch (Institut National de Veille Sanitaire) and of the regional 
epidemiological observatory. These two structures are just 
interested by a set of statistical indicators without any 
knowledge of the patient name. 
In the surveillance network we are proposing, the use of grid 
technology allows leaving all the data in the laboratories where 
they are produced. Moreover, the grid security framework allows 
also granting to the anatomical pathology laboratories a 
complete control on the access rights to their data. This should 
reduce the fear to loose control on their data. The network 
targets initially the actors of cancer surveillance but the patients 
could be considered as users in a second step as shown in Fig. 
(4). The use case is presently being implemented in the French 
Auvergne region using grid technology developed by the EGEE 
and Auvergrid projects. 
 
In the next section, we describe the architecture and services of a 
surveillance network on avian flu built using grid technology, 
which could provide useful services to the research community 
for both drug discovery and epidemiology. 
 
 
 
Scheme (1). Structures of the five known inhibitors in the library. 
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Fig (1). Histogram of compounds against T06. Those portions 
that control compounds fall into are colored in red. 
 
 
 
Fig (2). Heat map of compounds ordered by their docking 
energies against T06 and colored by their docking energies 
against each target. It is clear to see that single site mutation 
affect compound binding to targets. The effect is more obvious 
in mutation targets T01, T03, and T05. 
Fig (3). Histogram of compounds against T01.Control 
compounds are shown to decrease docking energies in this 
variant. 
 
 
Table (1). Summary of mutation effect on the control 
compounds from the modelling. The "+" sign indicates the 
compound is within top 5%; The "-" sign indicates the 
compound is not within the top 5%. 
 
 T06 T01 T02 T03 T05 T07 T13 
DAN - - - - - - - 
4AM - - + + - - - 
49A + - + + + - - 
GNA + - + - + - + 
G39 + - - - + - + 
Fig (4). Cancer surveillance network using grid technology  
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GRID TECHNOLOGY ENABLED SURVEILLANCE 
NETWORK ON AVIAN FLU 
The ability of the international community to respond efficiently 
to the possible emergence of a human-to-human transmissible 
avian influenza virus depends on its capacity to quickly assess 
any evolution of the disease. The countries which have been 
most exposed to avian flu have set up very efficient national 
networks for collecting data and monitoring the outbreaks.  
Unfortunately, there is no efficient international surveillance 
network so far that allows sharing the data collected at national 
level. However, more and more public resources are currently 
storing sequences of the virus strains and gathering useful 
information to the research community. 
The Influenza Virus Resource 
(http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html) at the 
National Center for Biotechnology Information (NCBI) and the 
Influenza Sequence Database (ISD) at Los Alamos National 
Laboratory are the two main repositories currently available. A 
significant effort has been made worldwide to sequence viral 
isolates in order to obtain nucleotide and protein information. 
Other resources focus more on curating and corroborating 
collected informations: this data processing is necessary to solve 
inaccuracy or repetition due to researchers direct submission to 
the database. Indeed the Influenza Virus Database 
(http://influenza.big.ac.cn/) from the Beijing Institute of 
Genomics - Chinese Academy of Sciences hosts around 50,000 
sequences and provides tools to analyze genomes, genes, genetic 
polymorphisms and phylogenetic relationships. ISD also provide 
curated data but not for free [22]. 
An interim Influenza Virus Tracking System 
(https://www.who.int/fluvirus_tracker) is hosted by the World 
Health Organization (WHO). The interim system contains data 
for the majority of viruses and clinical specimens that have been 
shared with this organization since November 2007, as well as 
all H5N1 viruses that have been developed into reassortant 
viruses as potential vaccine candidates. Data entry is ongoing. 
Through hundreds of missions, the Food and Agriculture 
Organization (FAO) has worked with affected and at-risk 
countries to facilitate capacity building, information sharing and 
networking. (http://www.fao.org/avianflu/en/index.html). FAO 
provides services to reinforce global avian influenza surveillance 
and early warning capabilities. 
 
The proposed surveillance network would federate national data 
repositories on avian flu together with international public 
resources previously described. The services to implement in 
priority are those addressing the main concerns of the 
international community, namely the evolution of the virus and 
its capacity for human-to-human transmission. For this purpose, 
services for molecular epidemiology and in silico drug discovery 
are extremely relevant: they both rely on the virus sequences. 
Modelling of pandemics propagation appears also as an 
important service, which requires the availability of up to date 
geographical distribution of the outbursts.  
The grid technology to build such a monitoring network has 
been developed in the recent years. Development of standards 
for interoperability allows a joint deployment across grid 
infrastructures all around the world.  
Such a worldwide surveillance network would involve many 
stakeholders: 
- International organizations like WHO or FAO. 
- National public health institutes and centers for disease control 
like National Institute for Sanitary Watch 
- Research laboratories on infectious diseases like Institut 
Pasteur. 
These stakeholders act as data providers or customers of the 
services provided by the network.  
 
More generally, the quality of the surveillance depends on 
several parameters: 
- The design and deployment of a robust federation of databases 
on multiple sites worldwide. 
- The reliability, relevance, completeness of the data stored. 
Reliability has to do with the mechanism to collect data. 
Relevance has to do with the mechanism to update data while 
completeness has to do with the capacity to collect data from 
multiple scientific disciplines and multiple countries. 
- The relevance of the services offered. It is not sufficient to have 
the best, most up-to-date information on the disease. The data 
must be properly integrated and its exploitation must build upon 
expert skills in molecular epidemiology and bioinformatics. 
- The user friendliness of the environment. Scientists are so busy 
they will not take time to contribute information and operate 
services if these services are not easy to use.  
- The reliability of the security framework. 
 
A key to the success is that users ought to be able to take for 
granted that the security mechanisms are sufficient to protect 
their data and that the results of their research will be private and 
available to third parties only if desirable. Indeed a significant 
delay remains - at least several months – before the new 
sequenced strains are included in the database to allow scientists 
to publish on these new sequences. This creates an unsatisfactory 
situation where possible mutations leading to human-to-human 
transmission could remain hidden for several weeks or months to 
the scientific community. Grid technology is now sufficiently 
mature to provide the secured framework fulfilling these 
requirements. Indeed, the grid certificates, created firstly to 
authenticate an user on the grid can easily be used to several 
purposes: set up a trusted client-server connexion between 
actors, perform rights managements between data holders and 
users or logging (connexion and usage of resources).  Such a 
framework is currently being tested on the cancer surveillance 
network described in section 4 where the different anatomical 
pathology laboratories manage and control the usage of their 
data. In order to improve the security, the certificate can be 
stored on a personal smart card, widely use in France health 
system. 
Applied to the avian flu surveillance network, it means that a 
biologist committing data to the network would keep the 
privilege of granting access rights to his/her data and possibly 
restricting it to collaborators or partners. In case of emergency, 
access to the data could be granted to an emergency panel for 
pandemics risk evaluation without compromising the ability for 
the biologist to later on publish analysis of the data.  
 
We are going to further detail the services to be offered by the 
proposed surveillance network. 
Molecular epidemiology 
The H5N1 epidemic has been characterized by a constant 
evolution of the virus genetic content, as it is the case for all the 
other influenza viruses. The main risk of pandemics comes from 
mutations which would induce human-to-human transmission. 
Monitoring of the evolution of the different virus strains is 
therefore a necessity for the research community. It must include 
both human and bird cases and starts at a very local level 
whenever an outburst takes place. National networks have been 
set up to quickly collect virus sample, analyze it to confirm the 
origin of death and sequence the virus strain involved. Once the 
virus sequence is available, its phylogenetic analysis requires a 
comparison with all the other virus strains sequenced which is a 
CPU consuming task even for small viruses. A service for 
automatic computation of phylogenetic relationships between 
molecular sequences and reconstruction of a robust phylogenetic 
tree from a set of sequences is then performed on grid using the 
best open source phylogenetic software codes. A biological 
meaningful approach is the deployment of distributed workflows 
for comparative phyloinformatics using different algorithms for 
a constant monitoring of molecular evolution at both macro level 
(within the group of viruses) and micro level (within the group 
of strains) [23]. 
 
Grid is a pleasant solution, with its large number of distributed 
CPU available, to deploy such workflows suffering from long 
runtimes due to their high degree of computational complexity 
as well as the large datasets involved.  
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In silico drug discovery 
Once a new virus strain is identified, the 3D structure of its 
enzymes can be derived from the already available H5N1 
structures in PDB using homology modelling. These new 
structures can be docked against the already known drugs to 
evaluate, in silico, the potential impact of the mutations on the 
drug efficiency.  
Another approach - as explained in section 3 - is virtual 
screening on grid to identify possible new hits and/or new 
scaffolds. Grids enable storage and automatic update of 
databases of chemical compounds ready for molecular modelling 
allowing a rapid deployment of in silico experiments when a 
new crystallized or modelled 3D structure becomes available in 
research community. A similar initiative is already available 
through a global partnership forged over the PRAGMA grid 
development activities in order to build a scalable, global, and 
open knowledge environment for developing novel inhibitors: 
avian flu grid. (http://avianflugrid.pragma-grid.net/). 
 
The use of in silico docking methods is sometimes the only 
possible strategy when the infectious agent cannot be propagated 
safely or with sufficient reproducibility in a laboratory 
environment. Results will provide important information 
concerning chemical features of potential inhibitors and their 
binding mode allowing further QSAR (Quantitative structure-
activity relationship) studies.  
Pandemics propagation modelling 
If the virus acquires the ability to transmit from human-to-
human, it will take more than 6 months to develop a vaccine to 
protect populations. Influenza pandemic planning is a complex, 
multifactorial process, raising the need to understand from now 
how influenza pandemics spread, both over time and 
geographically. In 2007, an international team of physicians and 
epidemiologists completed a study on the possible scenarios of 
the propagation of an avian influenza pandemic, under the 
hypothesis of person-to-person virus transmission [24]. 
Mathematical models allow to model temporal and geographical 
spread of avian flu based on virulence of transmission and 
conditions of its starting point (a flu starting in the summer does 
not propagate as easily as in winter). 
At the laboratory MSI (IFI, Hanoi, Vietnam), in 2007-2008, a 
work on modelling of the spread of avian influenza in a province 
of North Vietnam in collaboration with CIRAD (French 
Agricultural Research Centre working for International 
Development) has been done. This is an application on a new 
simulation platform called GAMA (Gis & Agent-based 
Modelling Architecture) which aims at providing field experts, 
modellers, and computer scientists, a complete modelling and 
simulation development environment for building spatially 
explicit multi-agent simulations. The goal is to simulate the 
poultry value chain of a whole province using geo-localised data, 
and use this to optimize a monitoring network [25]. Moreover, 
the researchers claim that a combination of an agent-based 
model and a SIG-based environmental model can act as a 
“virtual laboratory” for epidemiology. Following the needs 
expressed by epidemiologists studying micro-scale dynamics of 
avian influenza in Vietnam, and after a review of the 
epidemiological models proposed so far, an improved model, 
always built on top of the GAMA platform has been developed 
and adapted to the epidemiologists’ requirements. One notable 
contribution of this work is the treatment of the environment 
together with the social structure and animals’ behaviours, as a 
first-class citizen in the model, allowing epidemiologists to 
consider heterogeneous micro and macro factors in their 
exploration of the causes of the epidemics [26]. 
 
Grid technology can be a great solution to share and organize 
data in order to improve computational models and design 
probable scenarios. Grid can supply its calculation power to a 
larger simulation schema or allow even realizing a distributed 
simulation at world scale. 
 
CONCLUSION 
In this paper, we have discussed the opportunity for addressing 
evolution of a virus and its capacity for human-to-human 
transmission to deploy a surveillance network in the case of 
avian flu taking advantage of the recent developments of an 
emerging technology: the grid. We have shown how grids were 
already used to deploy innovative in silico approaches for 
molecular epidemiology and virtual screening on avian flu. From 
the field of oncology, we have provided the example of a 
surveillance network empowered by the grid where the different 
data sources are federated and queried remotely through a 
secured framework. 
Many contacts have been taken with international organizations 
(FAO, WHO), research laboratories and Centers for Disease 
Control and Prevention throughout Africa (Egypt), America 
(US), Asia (China, Korea, Thailand, Vietnam, Taiwan), and 
Europe (France, Italy, UK) in the last year to foster the 
emergence of this network which is a huge enterprise and has to 
be done in a very progressive way. As a first step, the work will 
focus on setting up molecular epidemiology and virtual 
screening services on the EGEE grid infrastructure to 
demonstrate the relevance of the approach to the Public Health 
authorities. 
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